Autogenous vaccines were introduced in the early twentieth century with increasing evidence of their effectiveness against certain infections. These vaccines are based on activating the individual's immune system to produce immunity to the infectious agent and are generally made by an individual or a small group. With a disease and can be applied to various bacterial and viral infections. Autogenous vaccines are quite similar to conventional vaccines in their uses, but they differ and may be preferred over conventional vaccines in certain areas for veterinary use in different countries. The use of this type of vaccine in humans is limited and has not been widely approved due to a lack of scientific evidence and research.
Over the years there has been a growing demand for autogenous vaccines derived from strains of bacteria because of their higher potency compared to strains of virus. Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the strains of bacteria commonly used to grow autogenic bacteria. The increasing prevalence of bacterial infections in animals, the preference for autogenous vaccines over antibiotics, and increased funding and support for the international eradication of animal diseases are likely to increase the demand for autogenous bacterial vaccines in the forecast period. A number of varied contagious diseases afflict animals. Some of these include peste des petits ruminants (PPR) or goat plague, a major challenge in the animal healthcare. Increasing government initiatives and investment in the healthcare sector plays a major role in the growth of autogenous vaccines market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the autogenous vaccine market. In addition, complete analysis of changes on the autogenous vaccine market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on North America economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
Autogenous vaccine market comprises of different market segment like by strain, end user and country.
The North America autogenous vaccine market includes key segments like bacterial strain and viral strain. The bacterial strain leads the segment accounting the largest market share during the forecast period. The increasing prevalence of bacterial infections among animal, increased funding and support for international animal disease eradication, preference toward bacterial strain autogenous vaccines over antibiotics are boosting the growth of bacterial strain in the North America autogenous vaccine market.
The autogenous vaccine market finds its major end user in livestock farming companies, veterinary research institutes, veterinary clinics and hospitals. The veterinary clinics and hospitals segment dominates the market holding the largest market share and is expected to grow in the forecast period. The increasing clinics in the region and also veterinary clinics offer preventative health care plans for pets contribute the growing clinics and boosts the growth of the autogenous vaccine market. The autogenous vaccines remain a regulatory issue as they are highly used by veterinarians and by animal owners.
The North America autogenous vaccine market is studied for the following countries like United States, Canada and Mexico. United States dominate the market due to increasing number of emergence of infectious diseases, the large population of animals suffering from diseases and ongoing veterinary vaccine projects will boost the market in the North America region. Increasing animal care spending and research & development activities in the veterinary biologics sector further favors the growth of the autogenous vaccines market in North America.
The key players in autogenous vaccine market are Boehringer Ingelheim International, Elanco Animal Health, Ceva (Ceva Biovac), Phibro Animal Health Corporation, UVAXX Pte Ltd, Bimeda, Deltamune Animal Health, Epitopix, Genova Labs, Newport Laboratories, Hygieia Biological Laboratories, Vaxxinova, Elanco Animal Health, Addison Biological Laboratory, Phibro Animal Health Corporation and LOHMANN TIERZUCHT GmbH among others.
October 2019: Ceva entered into a license agreement with ProBioGen AG for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR technology.
September 2019: Agri Labs (Huvepharma, Inc.) established a new fermentation plant in Peshtera, Southern Bulgaria. This increases Huvepharma’s total production capacity by 30%. Huvepharma now has flexibility to ferment its entire current product portfolio in one place, with additional capacity remaining to introduce new products to their range in the future.
April 2018: Pharmaq announced the production of fish vaccines at a development center in Suzhou, China. Pharmaq, now owned by Zoetis, and the parent company is also ramping up vaccine R&D for other species.
March 2018: Apiam acquired Passionate Vetcare, a regional veterinary clinic in the north west of Bendigo, to support the opening of Apiam’s Bendigo Emergency & Referral Centre for servicing in the Central Victorian region.
March 2018: Ceva launched innovative programs to promote the production of autogenous poultry vaccines by focusing on more sustainable production.
The report analyses the autogenous vaccine market based on segment like by strain, end user and country. The autogenous vaccine market includes key segments like bacterial strain and viral strain. The bacterial strain leads the market due to increasing use of antimicrobials in animals usually leads to the production of resistant bacteria that can be transmitted to humans through the food chain or by direct contact due to the severity the use of antibiotics in animals producing food, veterinarians and pig farmers is increasing . The autogenous vaccine market finds its major end user in livestock farming companies, veterinary research institutes, veterinary clinics and hospitals. The veterinary clinics and hospitals segment dominates the market as the veterinarians and pig farmers is increasing and to protect the animals from any bacterial infection and rising awareness of autogenous vaccine is boosting the growth of autogenous vaccine market in North America. By country the United States dominate the market due to increasing number of emergence of infectious diseases, the large population of animals suffering from diseases and ongoing veterinary vaccine projects will boost the autogenous vaccine market. The North America autogenous vaccine market is studied for the following countries like United States, Canada and Mexico.
Why to buy this report: